- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | PainReform Ltd: PainReform Announces Closing of $4 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 16.04. | PainReform prices its $4M offering at $0.80 apiece; shares fall | 1 | Seeking Alpha | ||
| 16.04. | PAINREFORM LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 15.04. | PAINREFORM LTD. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 09.04. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 09.04. | PainReform Ltd: PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions | 56 | GlobeNewswire (Europe) | TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation... ► Artikel lesen | |
| 09.04. | EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions | 1 | Benzinga.com | ||
| 02.04. | PainReform Ltd: PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy | 71 | GlobeNewswire (Europe) | TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation... ► Artikel lesen | |
| 02.04. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.04. | EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug | 1 | Benzinga.com | ||
| 01.03. | PainReform files to sell shares | 1 | Seeking Alpha | ||
| 01.03. | PAINREFORM LTD. - F-1, Registration statement for certain foreign private issuers | 2 | SEC Filings | ||
| 01.03. | PainReform advances in phase 3 bunionectomy trial | 1 | Investing.com | ||
| 01.03. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 01.03. | PainReform Ltd: PainReform Provides Year-End Business Update | 264 | GlobeNewswire (Europe) | Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy Remains on track to announce top-line data by mid-2024 TEL AVIV, Israel, March 01, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 29.02. | PAINREFORM LTD. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 22.01. | DealFlow Events: PainReform to Present at the Microcap Conference in Atlantic City | 348 | Newsfile | Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation... ► Artikel lesen | |
| 22.01. | PainReform Ltd: PainReform to Present at the Microcap Conference in Atlantic City | 1 | GlobeNewswire (USA) | ||
| 12.01. | PainReform files to sell 968,545 ordinary shares for holders | 1 | Seeking Alpha | ||
| 03.01. | PAINREFORM LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 8,750 | +1,74 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 3,665 | +4,12 % | What's Going On With Rocket Lab Shares Today? | ||
| BOIRON | 33,850 | -0,88 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| MEDICINOVA | 1,080 | -10,00 % | MediciNova, Inc.: MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) | LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 6,700 | 0,00 % | Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders | SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,235 | -3,86 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
| HARROW | 10,520 | +1,06 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,510 | +5,59 % | CUMBERLAND PHARMACEUTICALS INC - 8-K, Current Report | ||
| SHINECO | 0,849 | +6,66 % | SHINECO, INC. - 8-K, Current Report | ||
| CYANOTECH | 0,260 | 0,00 % | Delisting of Securities of NanoString Technologies, Inc.; Remark Holdings, Inc.; Sunworks, Inc.; Cyanotech Corporation; Sientra, Inc.; Charge Enterprises, Inc. and others from The Nasdaq Stock Market | NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of NanoString Technologies, Inc. NanoString Technologies, Inc.'s securities... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 3,210 | +4,90 % | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| BAYER | 28,130 | +2,85 % | Bayer: Dauerthema Glyphosat | In der EU hat der umstrittene Unkrautvernichter Glyphosat im vergangenen Jahr eine weitere Zulassung erhalten. In Deutschland hingegen sollen die Anwendungsbeschränkungen unabhängig von der EU-Entscheidung... ► Artikel lesen | |
| MERCK KGAA | 150,30 | +0,91 % | Tagesausblick für 26.04.: DAX - Zinsen drücken. Bayer, Conti und Merck laden zur HV | ||
| CANOPY GROWTH | 10,340 | -25,82 % | Aurora Cannabis & Canopy Growth stürzen ab - was ist los? | Um mehr als -20% sind am deutschen Feiertag die Aurora Cannabis-Aktie (WKN: A2P4EC) und die Aktie von Canopy Growth (WKN: A140WQA) an der Nasdaq abgestürzt. Was ist los im Cannabis-Sektor? Und wie geht... ► Artikel lesen | |
| NOVO NORDISK | 116,60 | -2,65 % | Novo Nordisk-Aktie: Wie stark belasten die US-Vorwürfe? | Die Novo Nordisk-Aktie (WKN: A3EU6F) muss am Mittwoch einen Dämpfer verkraften, nachdem die amerikanische Regierung plötzlich den Pharmagiganten ins Auge gefasst hat. Kann das zum Problem für den Konzern... ► Artikel lesen |
PAINREFORM LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
